CatalystS-1 Filing

$MPLT -1.7% — MAPLIGHT THERAPEUTICS FILES $250.75M IPO TO FUND PHASE 2 CNS PROGRAMS

MPLT

$7.58

-1.81%

What changed

Clinical-stage biopharma plans $17/sh range. Proceeds earmarked for ML-007C-MA schizophrenia and Alzheimer's psychosis trials, plus ML-004 autism. Lead underwriters: Morgan Stanley, Jefferies, Leerink, Goldman Sachs.

Why it matters

Sources

sec